Diverse manifestations and evolving treatments of autoimmune hepatitis

Minerva Gastroenterologica e Dietologica

Volumn 51, Issue 4, 2005, Pages 313-333

  Czaja, A J ^a  

^a MAYO CLINIC   (United States)

Author keywords

Autoimmunity; Genetics; Hepatitis

Indexed keywords

ANTIGEN; ANTINUCLEAR ANTIBODY; ASIALOGLYCOPROTEIN RECEPTOR ANTIBODY; AUTOANTIBODY; AZATHIOPRINE; BUDESONIDE; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN; DICLOFENAC; HLA ANTIGEN; IMMUNOSUPPRESSIVE AGENT; LIVER ANTIBODY; MERCAPTOPURINE; METHOTREXATE; MINOCYCLINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NITROFURANTOIN; PERINUCLEAR NEUTROPHIL CYTOPLASMIC ANTIBODY; PREDNISONE; RECOMBINANT INTERLEUKIN 10; SMALL INTERFERING RNA; T LYMPHOCYTE VACCINE; TACROLIMUS; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG; URSODEOXYCHOLIC ACID; VACCINE;

ANTIBODY SPECIFICITY; AUTOIMMUNE HEPATITIS; CLINICAL FEATURE; DIAGNOSTIC PROCEDURE; DISEASE CLASSIFICATION; ETHNOLOGY; GENE SILENCING; GENE THERAPY; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HEPATITIS C VIRUS; HEREDITY; HISTOLOGY; HISTOPATHOLOGY; HUMAN; IMMUNOLOGICAL TOLERANCE; NONHUMAN; OUTCOME ASSESSMENT; RACE DIFFERENCE; REVIEW; SCORING SYSTEM; SEROLOGY; T LYMPHOCYTE; TREATMENT OUTCOME; VACCINATION;

HEPATITIS, AUTOIMMUNE; HLA-DR ANTIGENS; HUMANS; PHENOTYPE;

EID: 29444453466     PISSN: 00264776     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (190)

1. Czaja AJ, Freese DK. Diagnosis and treatment of autoimmune hepatitis. Hepatology 2002;36:479-97.
2. Boberg KM, Aadland E, Jahnsen J, Raknerud N, Stiris M, Bell H. Incidence and prevalence of primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis in a Norwegian population. Scand J Gastroenterol 1998;33:99-103.
3. nd ed. New York: Elsevier Science Publishers; 1998.p.1-20.
4. Seaberg EC, Belle SH, Beringer KC, Schivins JL, Detre KM. Liver transplantation in the United States from 1987-1998: updated results from the Pitt-UNOS liver transplant registry. In: Cecka JM, Terasaki PI editors. Clinical Transplants 1998. Los Angeles: UCLA Tissue Typing Laboratories; 1999.p.17-37.
5. Czaja AJ, Carpenter HA. Decreased fibrosis during corticosteroid therapy of autoimmune hepatitis. J Hepatol 2004;40:644-50.
6. Roberts SK, Therneau T, Czaja AJ. Prognosis of histological cirrhosis in type 1 autoimmune hepatitis. Gastroenterology 1996;110:848-57.
7. Alvarez F, Berg PA, Bianchi FB, Bianchi L, Burroughs AK, Cancado EL et al. International Autoimmune Hepatitis Group report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999;31:929-38.
8. Czaja AJ. The variant forms of autoimmune hepatitis. Ann Intern Med 1996;125:588-98.
9. Czaja AJ, Carpenter HA. Validation of a scoring system for the diagnosis of autoimmune hepatitis. Dig Dis Sci 1996;41:305-14.
10. Nikias GA, Batts KP, Czaja AJ. The nature and prognostic implications of autoimmune hepatitis with an acute presentation. J Hepatol 1994;21:866-71.
11. Porta G, Da Costa Gayotto LC, Alvarez F. Anti-liver-kidney microsome antibody-positive autoimmune hepatitis presenting as fulminant liver failure. J Fed Gastroenterol Nutrition 1990;11:138-40.
12. Kessler WR, Cummings OW, Eckert G, Chalasani N, Lumeng L, Kwo PY. Fulminant hepatic failure as the initial presentation of acute autoimmune hepatitis. Clin Gastroenterol Hepatol 2004;2:625-31.
13. Burgart LJ, Batts KP, Ludwig J, Nikias GA, Czaja AJ. Recent onset autoimmune hepatitis: biopsy findings and clinical correlations. Am J Surg Path 1995;19:699-708.
14. Kogan J, Safadi R, Ashur Y, Shouval D, Ilan Y. Prognosis of symptomatic versus asymptomatic autoimmune hepatitis. A study of 68 patients. J Clin Gastroenterol 2002;35:75-81.
15. nd ed. Philadelphia: Current Medicine; 2000. 3.1-3.22.
16. Abraham S, Begum S, Isenberg D. Hepatic manifestations of autoimmune rheumatic diseases. Ann Rheum Dis 2004;63:123-9.
17. Clemente MG, Meloni A, Obermayer-Staub P, Frau F, Manns MP, De Virgiliis S. Two cytochromes P450 are major hepatocellular autoantigens in autoimmune polyglandular syndrome type 1. Gastroenterology 1998;114:324-8.
18. Aaltonen J, Borses P, Sandkuijl L, Perheentupa J, Peltonen L. An autosomal locus causing autoimmune disease: autoimmune polyglandular disease type 1 assigned to chromosome 21. Nat Genet 1994;8:83-7.
19. Volta U, De Franceschi L, Molinaro N, Cassani F, Muratori L, Lenzi M et al. Frequency and significance of anti-gliadin and anti-endomysial antibodies in autoimmune hepatitis. Dig Dis Sci 1998;43:2190-5.
20. Abdo A, Meddings J, Swain M. Liver abnormalities in celiac disease. Clin Gastroenterol Hepatol 2004;2:107-12.
21. Kaukinen K, Halme L, Collin P, Farkkila M, Maki M, Vehmanen P et al. Celiac disease in patients with severe liver disease: gluten-free diet may reverse hepatic failure. Gastroenterology 2002;122:881-8.
22. Sedlack RE, Smyrk TC, Czaja AJ, Talwalkar JA. Celiac-disease-associated autoimmune cholangitis. Am J Gastroenterol 2002;97:3196-8.
23. Volta U, Rodrigo L, Granito A, Petrolinin N, Muratori P, Muratori L et al. Celiac disease in autoimmune cholestatic liver disorders. Am J Gastroenterol 2002;97:2609-13.
24. Gomez JC, Selvaggio G, Pizarro B, Viola MJ, Motta GL, Smecuol E et al. Value of a screening algorithm for celiac disease using tissue transglutaminase antibodies as first level in a population-based study. Am J Gastroenterol 2002;97:2785-90.
25. Carroccio A, Giannitrapani L, Soresi M, Not T, Iacono G, Di Rosa C et al. Guinea pig transglutaminase immunolinked assay does not predict coeliac disease in patients with chronic liver disease. Gut 2001;49: 506-11.
26. Vecchi M, Folli C, Donato MF, Formenti S, Arosio E, De Franchis R. High rate of positive anti-tissue transglutaminase antibodies in chronic liver disease. Role of liver decompensation and of the antigen source. Scand J Gastroenterol 2003;38:50-4.
27. Cummins A, Thompson F. Sensitivity of anti-endomysial antibody in detecting celiac disease. Gastroenterology 2002;122:246-7.
28. Czaja AJ, Bianchi FB, Carpenter HA, Krawitt EL, Lohse AW, Manns MP et al. Treatment challenges and investigational opportunities in autoimmune hepatitis. Hepatology 2005;41:207-15.
29. Lim KN, Casanova RL, Boyer TD, Bruno CJ. Autoimmune hepatitis in African Americans: presenting features and responses to therapy. Am J Gastroenterol 2001;96:3390-4.
30. Nakamura K, Yoneda M, Yokohama S, Tamori K, Sato Y, Aso K et al. Efficacy of ursodeoxycholic acid in Japanese patients with type 1 autoimmune hepatitis. J Gastroenterol Hepatol 1998;13:490-5.
31. Czaja AJ, Souto EO, Bittencourt PL, Cancado ELR, Porto G, Goldberg AC et al. Clinical distinctions and pathogenic implications of type 1 autoimmune hepatitis in Brazil and the United States. J Hepatol 2002;37:302-8.
32. Hurlburt KJ, McMahon BJ, Deubner H, Hsu-Trawinski B, Williams JL, Kowdley KV. Prevalence of autoimmune hepatitis in Alaska natives. Am J Gastroenterol 2002;97:2402-7.
33. Zolfino T, Heneghan MA, Norris S, Harrison PM, Portmann BC, McFarlane IG. Characteristics of autoimmune hepatitis in patients who are not of European Caucasoid ethnic origin. Gut 2002;50:713-7.
34. Czaja AJ, Carpenter HA. Sensitivity, specificity and predictability of biopsy interpretations in chronic hepatitis. Gastroenterology 1993;105:1824-32.
35. Carpenter HA, Czaja AJ. The role of histologic evaluation in the diagnosis and management of autoimmune hepatitis and its variants. Clin Liver Dis 2002;6: 685-705.
36. Czaja AJ, Carpenter HA. Histological findings in chronic hepatitis C with autoimmune features. Hepatology 1997;26:459-66.
37. Czaja AJ, Carpenter HA, Santrach PJ, Moore SB. Autoimmune cholangitis within the spectrum of autoimmune liver disease. Hepatology 2000;31:1231-8.
38. Czaja AJ, Carpenter HA. Autoimmune hepatitis with incidental histologic features of bile duct injury. Hepatology 2001;34:659-65.
39. Loria P, Lonardo A, Leonardi F, Fontana C, Carulli L, Verrone AM et al. Non-organ-specific autoantibodies in nonalcoholic fatty liver disease: prevalence and correlates. Dig Dis Sci 2003;48:2173-81.
40. Adams LA, Lindor KD, Angulo P. The prevalence of autoantibodies and autoimmune hepatitis in patients with nonalcoholic fatty liver disease. Am J Gastroenterol 2004;99:1316-20.
41. Ludwig J, Czaja AJ, Dickson ER, LaRusso NF, Wiesner RH. Manifestations of nonsuppurative cholangitis in chronic hepatobiliary disease: morphologic spectrum, clinical correlations and terminology. Liver 1984;4: 105-16.
42. Ludwig J, Barham SS, LaRusso NF, Elveback LR, Wiesner RH, McCall JT. Morphologic features of chronic hepatitis associated with primary sclerosing cholangitis or chronic ulcerative colitis. Hepatology 1981;1:632-40.
43. Pratt DS, Fawaz KA, Rabson A, Dellelis R, Kaplan MM. A novel histological lesion in glucocorticoid-responsive chronic hepatitis. Gastroenterology 1997;113:664-8.
44. Singh R, Nair S, Farr G, Mason A, Perrillo R. Acute autoimmune hepatitis presenting with centrizonal liver disease: case report and review of the literature. Am J Gastroenterol 2002;97:2670-3.
45. Okano N, Yamamotos K, Sakaguchi K, Miyake Y, Shimada N, Hakoda T et al. Clinicopathological features of acute-onset autoimmune hepatitis. Hepatol Res 2003;25:263-70.
46. Czaja AJ, Muratori P, Muratori L, Carpenter HA, Bianchi FB. Diagnostic and therapeutic implications of bile duct injury in autoimmune hepatitis. Liver International 2004;24:322-9.
47. Rabinovitz M, Demetris AJ. Postinfantile giant cell hepatitis associated with anti-M2 mitochondrial antibodies. Gastroenterology 1994;107:1162-4.
48. Protzer U, Dienes HP, Bianchi L, Lohse AW, Helmreich-Becker I, Gerken G et al. Postinfantile giant cell hepatitis in patients with primary sclerosing cholangitis and autoimmune hepatitis. Liver 1996;16:274-82.
49. Ben-Ari Z, Broida E, Monselise Y, Kazatsker A, Baruch J, Pappo O et al. Syncytial giant-cell, hepatitis due to autoimmune hepatitis type II (LKM1+) presenting as subfulminant hepatitis. Am J Gastroenterol 2000;95: 799-801.
50. Thijs JC, Bosma A, Henzen-Logmans SC, Meuwissen SG. Postinfantile giant cell hepatitis in a patient with multiple autoimmune features. Am J Gastroenterol 1985;80:294-7.
51. Lau JYN, Koukoulis G, Mieli-Vergani G, Portmann BC, Williams R. Syncytial giant-cell hepatitis-a specific disease entity? J Hepatol 1992;15:216-9.
52. Phillips MJ, Blendis LM, Poucell S, Patterson J, Petric M, Roberts E et al. Syncytial giant-cell hepatitis. Sporadic hepatitis with distinctive pathological features, a severe clinical course, and paramyxoviral features. N Engl J Med 1991;324:455-60.
53. Fraquelli M, Colli A, Cocciolo M, Conte D. Adult syncytial giant cell chronic hepatitis due to herbal remedy. J Hepatol 2000;33:505-8.
54. Czaja AJ, Norman GL. Autoantibodies in the diagnosis and management of liver disease. J Clin Gastroenterol 2003;37:315-29.
55. Doherty DG, Penzotti JE, Koelle DM, Kwok WW, Lybrand TP, Masewicz S et al. Structural basis of specificity and degeneracy of T cell recognition: pluriallelic restriction of T cell responses to a peptide antigen involves both specific and promiscuous interactions between the T cell receptor, peptide, and HLA-DR. J Immunol 1998;161:3527-35.
56. Czaja AJ. Autoimmune chronic active hepatitis-a specific entity? The negative argument. J Gastroenterol Hepatol 1990;5:343-51.
57. Czaja AJ. Autoantibodies in autoimmune liver disease. Adv Clin Chem 2005;40:127-64.
58. Czaja AJ. Behavior and significance of autoantibodies in type 1 autoimmune hepatitis. J Hepatol 1999;30: 394-401.
59. Czaja AJ, Manns MP, Homburger HA. Frequency and significance of antibodies to liver/kidney microsome type 1 in adults with chronic active hepatitis. Gastroenterology 1992;103:1290-5.
60. Lidman K, Biberfield G, Fagraeus A, Norberg R, Tortensson R, Utter G et al. Anti-actin specificity of human smooth muscle antibodies in chronic active hepatitis. Clin Exp Immunol 1976;24:266-72.
61. Fusconi M, Cassani F, Zauli D, Lenzi M, Ballardini G, Volta U et al. Anti-actin antibodies: a new test for an old problem. J Immunol Methods 1990;130:1-8.
62. Cancado ELR, Vilas-Boas LS, Abrantes-Lemos CP, Novo NF, Porta G, Da Silva LC et al. Heat serum inactivation as a mandatory procedure for antiactin antibody detection in cell culture. Hepatology 1996;23:1098-104.
63. Czaja AJ, Cassani F, Cataleta M, Valentini P, Bianchi FB. Frequency and significance of antibodies to actin in type 1 autoimmune hepatitis. Hepatology 1996;24: 1068-73.
64. McFarlane IG, Hegarty JE, McSorley CG, McFarlane BM, Williams R. Antibodies to liver-specific protein predict outcome of treatment withdrawal in autoimmune chronic active hepatitis. Lancet 1984;2:954-6.
65. Czaja AJ, Pfeifer KD, Decker RH, Vallari AS. Frequency and significance of antibodies to asialoglycoprotein receptor in type 1 autoimmune hepatitis. Dig Dis Sci 1996;41:1733-40.
66. Li L, Chen M, Huang DY, Nishioka M. Frequency and significance of antibodies to chromatin in autoimmune hepatitis type 1. J Gastroenterol Hepatol 2000;15: 1176-82.
67. Czaja AJ, Shums Z, Binder WL, Lewis SJ, Nelson VJ, Norman GL. Frequency and significance of antibodies to chromatin in autoimmune hepatitis. Dig Dis Sci 2003;48:1658-64.
68. Baeres M, Herkel J, Czaja AJ, Wies I, Kanzler S, Cancado ELR et al. Establishment of standardized SLA/LP immunoassays: specificity for autoimmune hepatitis, worldwide occurrence, and clinical characteristics. Gut 2002;51:259-64.
69. Czaja AJ, Shums Z, Norman GL. Frequency and significance of antibodies to soluble liver antigen/liver pancreas in variant autoimmune hepatitis. Autoimmunity 2002;35:475-83.
70. Ma Y, Okamoto M, Thomas MG, Bogdanos DP, Lopes AR, Portmann B et al. Antibodies to conformational epitopes of soluble liver antigen define a severe form of autoimmune liver disease. Hepatology 2002;35: 658-64.
71. Czaja AJ, Donaldson PT, Lohse AW. Antibodies to soluble liver antigen/liver pancreas and HLA risk factors in type 1 autoimmune hepatitis. Am J Gastroenterol 2002;97:413-9.
72. Czaja AJ, Carpenter HA, Manns MP. Antibodies to soluble liver antigen, P450IID6, and mitochondrial complexes in chronic hepatitis. Gastroenterology 1993;105: 1522-8.
73. Kanzler S, Weidemann C, Gerken G, Lohr HF, Galle PR, Meyer zum Buschenfelde KH et al. Clinical significance of autoantibodies to soluble liver antigen in autoimmune hepatitis. J Hepatol 1999;31:635-40.
74. Wies I, Brunner S, Henninger J, Herkel J, Meyer zum Buschenfelde KH, Lohse AW. Identification of target antigen for SLA/LP autoantibodies in autoimmune hepatitis. Lancet 2000;355:1510-5.
75. Costa M, Rodriques-Sanchez JL, Czaja AJ, Gelpi C. Isolation and characterization of cDNA encoding the antigenic protein of the human tRNA(Ser)Sec complex recognized by autoantibodies from patients with type 1 autoimmune hepatitis. Clin Exp Immunol 2000;121:364-74.
76. Vergani D, Alvarez F, Bianchi FB, Cancado ELR, Mackay IR, Manns MP et al. Liver autoimmune serology: a consensus statement from the committee for autoimmune serology of the International Hepatitis Group. J Hepatol 2004;41:677-83.
77. Czaja AJ, Manns MP. The validity and importance of subtypes of autoimmune hepatitis: a point of view. Am J Gastroenterol 1995;90:1206-11.
78. McFarlane IG. The relationship between autoimmune markers and different clinical syndromes in autoimmune hepatitis. Gut 1998;42:599-602.
79. Wang KK, Czaja AJ. Prognosis of corticosteroid-treated hepatitis B surface antigen-negative chronic active hepatitis in postmenopausal women: a retrospective analysis. Gastroenterology 1989;97:1288-93.
80. Schramm C, Kanzler S, Meyer zum Buschenfelde K-H, Galle PR, Lohse AW. Autoimmune hepatitis in the elderly. Am J Gastroenterol 2001;96:1587-91.
81. Czaja AJ, Davis GL, Ludwig J, Baggenstoss AH, Taswell HF. Autoimmune features as determinants of prognosis in steroid-treated chronic active hepatitis of uncertain etiology. Gastroenterology 1983;85:713-7.
82. Davis GL, Czaja AJ, Ludwig J. Development and prognosis of histologic cirrhosis in corticosteroid-treated HBsAg-negative chronic active hepatitis. Gastroenterology 1984;87:1222-7.
83. Perdigoto R, Carpenter HA, Czaja AJ. Frequency and significance of chronic ulcerative colitis in severe corticosteroid-treated autoimmune hepatitis. J Hepatol 1992;14:325-31.
84. Homberg J-C, Abuaf N, Bernard O, Islam S, Alvarez F, Khalil SH et al. Chronic active hepatitis associated with antiliver/kidney microsome antibody type 1: a second type of "autoimmune" hepatitis. Hepatology 1987;7:1333-9.
85. Mieli-Vergani G. Autoimmune sclerosing cholangitis: a distinct clinical entity? J Hepatol 2000;32 Suppl 2: 7-8.
86. Gregorio GV, Portmann B, Karani J, Harrison P, Donaldson PT, Vergani D et al. Autoimmune hepatitis/sclerosing cholangitis overlap syndrome in childhood: a 16-year prospective study. Hepatology 2001;33:544-53.
87. Gueguen M, Meunier-Rotival M, Bernard O, Alvarez F. Anti-liver kidney microsome antibody recognizes a cytochrome P450 from the IID subfamily. J Exp Med 1988;168:801-6.
88. Zanger UM, Hauri H-P, Loeper J, Homberg J-C, Meyer UA. Antibodies against human cytochrome P-450dbl in autoimmune hepatitis type II. Proc Natl Acad Sci USA 1988;85:8256-60.
89. Manns MP, Griffin KJ, Sullivan KF, Johnson EF. LKM-1 autoantibodies recognize a short linear sequence in P450IID6, a cytochrome P-450 monooxygenase. J Clin Invest 1991;88:1370-8.
90. Kerkar N, Choudhuri K, Ma Y, Mahmoud A, Bogdanos DP, Muratori L et al. Cytochrome P4502D6193-212: a new immunodominant epitope and target of virus/self cross-reactivity in liver kidney microsomal autoantibody type 1-positive liver disease. J Immunol 2003;170: 1481-9.
91. Yamamoto AM, Cresteil D, Homberg JC, Alvarez F. Characterization of the anti-liver-kidney microsome antibody (anti-LKM1) from hepatitis C virus-positive and -negative sera. Gastroenterology 1993;104: 1762-7.
92. Lunel F, Abuaf N, Frangeul L, Grippon P, Perrin M, Le Coz Y et al. Liver/kidney microsome antibody type 1 and hepatitis C virus infection. Hepatology 1992;16: 630-6.
93. Reddy KR, Krawitt EL, Homberg JC, Jeffers LJ, de Medina M, Chastenay B et al. Absence of anti-LKM1 in hepatitis C viral infection in the United States. J Viral Hepat 1995;2:175-9.
94. Durazzo M, Philipp T, van Pelt FNAM, Luttig B, Borghesio E, Michel G et al. Heterogeneity of microsomal autoantibodies (LKM) in chronic hepatitis C and D virus infection. Gastroenterology 1995;108: 455-62.
95. Gerotto M, Pontisso P, Giostra F, Francesconi R, Muratori L, Ballardini G et al. Analysis of the hepatitis C virus genome in patients with anti-LKM-1 autoantibodies. J Hepatol 1994;21:273-6.
96. Czaja AJ, Kruger M, Santrach PJ, Moore SB, Manns MP. Genetic distinctions between types 1 and 2 autoimmune hepatitis. Am J Gastroenterol 1997;92: 2197-200.
97. Bittencourt PL, Goldberg AC, Cancado ELR, Porta G, Carrilho FJ, Farias AQ et al. Genetic heterogeneity in susceptibility to autoimmune hepatitis types 1 and 2. Am J Gastroenterol 1999;94:1906-13.
98. Muratori P, Czaja AJ, Muratori L, Granito A, Pappas G, Cassani F et al. Evidence of a genetic basis for the different geographical occurrences of liver/kidney microsomal antibody type 1 in hepatitis C. World J Gastroenterol. In press.
99. Czaja AJ, Donaldson PT. Genetic susceptibilities for immune expression and liver cell injury in autoimmune hepatitis. Immunol Rev 2000;174:250-9.
100. Czaja AJ. Understanding the pathogenesis of autoimmune hepatitis. Am J Gastroenterol 2001;96:1224-31.
101. Czaja AJ, Doherty DG, Donaldson PT. Genetic bases of autoimmune hepatitis. Dig Dis Sci 2002;47:2139-50.
102. Donaldson PT, Czaja AJ. Genetic effects on susceptibility, clinical expression, and treatment outcome of type 1 autoimmune hepatitis. Clin Liver Dis 2002;6: 707-25.
103. Vergani D, Choudhuri K, Bogdanos DP, Mieli-Vergani G. Pathogenesis of autoimmune hepatitis. Clin Liver Dis 2002;6:727-37.
104. Czaja AJ. Autoimmune hepatitis after liver transplantation and other lessons of self-intolerance. Liver Transplantation 2002;8:505-13.
105. Donaldson PT, Doherty DG, Hayllar KM, McFarlane IG, Johnson PJ, Williams R. Susceptibility to autoimmune chronic active hepatitis: human leukocyte antigens DR4 and A1-B8-DR3 are independent risk factors. Hepatology 1991;13:701-6.
106. Czaja AJ, Carpenter HA, Santrach PJ, Moore SB. Significance of HLA DR4 in type 1 autoimmune hepatitis. Gastroenterology 1993;105:1502-7.
107. Seki T, Kiyosawa K, Inoko H, Ota M. Association of autoimmune hepatitis with HLA-Bw54 and DR4 in Japanese patients. Hepatology 1990;12:1300-4.
108. Seki T, Ota M, Furuta S, Fukushima H, Kondo T, Hino K et al. HLA class II molecules and autoimmune hepatitis susceptibility in Japanese patients. Gastroenterology 1992;103:1041-7.
109. Qiu D-K, Ma X. Relationship between human leukocyte antigen-DRB1 and autoimmune hepatitis type I in Chinese patients. J Gastroenterol Hepatol 2003; 18:63-7.
110. Vazquez-Garcia MN, Alaez C, Olivo A, Debaz H, Perez-Luque E, Burguete A et al. MHC class II sequences of susceptibility and protection in Mexicans with autoimmune hepatitis. J Hepatol 1998;28:985-90.
111. Muratori P, Czaja AJ, Muratori L, Pappas G, Maccariello S, Cassani F et al. Genetic predispositions to autoimmune hepatitis in Italian and North American patients. World J Gastroenterol 2005;11:1862-6.
112. Fainboim L, Marcos Y, Pando M, Capucchio M, Reyes GB, Galoppo C et al. Chronic active autoimmune hepatitis in children. Strong association with a particular HLA DR6 (DRB1*1301) haplotype. Hum Immunol 1994;41:146-50.
113. Pando M, Larriba J, Fernandez GC, Fainboim H, Ciocca M, Ramonet M et al. Pediatric and adult forms of type 1 autoimmune hepatitis in Argentina: evidence for differential genetic predisposition. Hepatology 1999;30: 1374-80.
114. Goldberg AC, Bittencourt PL, Mougin B, Cancado ELR, Porta G, Carrilho F et al. Analysis of HLA haplotypes in autoimmune hepatitis type 1: identifying the major susceptibility locus. Hum Immunol 2001;62: 165-9.
115. Strettell MDJ, Donaldson PT, Thomson LJ, Santrach PJ, Moore SB, Czaja AJ et al. Allelic basis for HLA-encoded susceptibility to type 1 autoimmune hepatitis. Gastroenterology 1997;112:2028-35.
116. Czaja AJ, Strettell MDJ, Thomson LJ, Santrach PJ, Moore SB, Donaldson PT et al. Associations between alleles of the major histocompatibility complex and type 1 autoimmune hepatitis. Hepatology 1997;25: 317-23.
117. Doherty DG, Donaldson PT, Underhill JA, Farrant JM, Duthie A, Mieli-Vergani G et al. Allelic sequence variation in the HLA class II genes and proteins in patients with autoimmune hepatitis. Hepatology 1994;19: 609-15.
118. Manns MP, Kruger M. Immunogenetics of chronic liver diseases. Gastroenterology 1994;106:1676-97.
119. Tapia-Conyer R, Santos JI, Cavalcanti AM, Urdaneta E, Rivera L, Manterola A et al. Hepatitis A in Latin America: a changing epidemiologic pattern. Am J Trop Med Hyg 1999;61:825-9.
120. Vento S, Garofano T, Di Perri G, Dolci L, Concia E, Bassetti D. Identification of hepatitis A virus as a trigger for autoimmune chronic hepatitis type 1 in susceptible individuals. Lancet 1991;337:1183-7.
121. Huppertz H-K, Treichel U, Gassel AM, Jeschke R, Meyer zum Buschenfelde K-H. Autoimmune hepatitis following hepatitis A virus infection. J Hepatol 1995;23:204-8.
122. Fainboim L, Velasco VCC, Marcos CY, Ciocca M, Roy A, Theiler G et al. Protracted, but not acute, hepatitis A virus infection is strongly associated with HLA-DRB1*1301, a marker for pediatric autoimmune hepatitis. Hepatology 2001;33:1512-7.
123. Czaja AJ, Santrach PJ, Moore SB. Shared genetic risk factors in autoimmune liver disease. Dig Dis Sci 2001; 46:140-7.
124. Czaja AJ, Dos Santos RM, Porto A, Santrach PJ, Moore SB. Immune phenotype of chronic liver disease. Dig Dis Sci 1998;43:2149-55.
125. Rowley MJ, Mackay IR. Measurement of antibody-producing capacity in man. I. the normal response to flagellan from Salmonella Adelaide. Clin Exp Immunol 1969;5:407-18.
126. Czaja AJ, Donaldson PT. Gender effects and synergisms with histocompatibility leukocyte antigens in type 1 autoimmune hepatitis. Am J Gastroenterol 2002;97:2051-7.
127. Whitacre CC, Reingold SC, O'Looney PA. A gender gap in autoimmunity. Science 1999;283:1277-8.
128. Buchel E, Van Steenbergen W, Nevens F, Fevery J. Improvement of autoimmune hepatitis during pregnancy followed by flare-up after delivery. Am J Gastroenterol 2002;97:3160-5.
129. Gregorio GV, Portmann B, Reid F, Donaldson PT, Doherty DG, McCartney M et al. Autoimmune hepatitis in childhood. A 20 year survey. Hepatology 1997; 25:541-7.
130. Wilder RL. Hormones and autoimmunity: animal models of arthritis. Baillieres Clinical Rheumatology 1996; 10:259-71.
131. Nelson JL. Microchimerism: implications for autoimmune disease. Lupus 1999;8:370-4.
132. Cookson S, Constantini PK, Clare M, Underhill JA, Bernal W, Czaja AJ et al. Frequency and nature of cytokine gene polymorphisms in type 1 autoimmune hepatitis. Hepatology 1999;30:851-6.
133. Czaja AJ, Cookson S, Constantini PK, Clare M, Underhill JA, Donaldson PT. Cytokine polymorphisms associated with clinical features and treatment outcome in type 1 autoimmune hepatitis. Gastroenterology 1999;117:645-52.
134. Agarwal K, Czaja AJ, Jones DEJ, Donaldson PT. CTLA-4 gene polymorphism and susceptibility to type 1 autoimmune hepatitis. Hepatology 2000;31:49-53.
135. Djilali-Saiah I, Ouellette P, Caillat-Zucman S, Debray D, Kohn JI, Alvarez F. CTLA-4/CD28 region polymorphisms in children from families with autoimmune hepatitis. Hum Immunol 2001;62:1356-62.
136. Bittencourt PL, Palacios SA, Cancado ELR, Porta G, Carrilho FJ, Laudanna AA et al. Cytotoxic T lymphocyte antigen-4 gene polymorphisms do not confer susceptibility to autoimmune hepatitis types 1 and 2 in Brazil. Am J Gastroenterol 2003;98:1616-20.
137. Vogel A, Strassburg CP, Manns MP. Genetic association of vitamin D receptor polymorphisms with primary biliary cirrhosis and autoimmune hepatitis. Hepatology 2002;35:126-31.
138. Vogel A, Strassburg CP, Manns MP. 77 C/G mutation in the tyrosine phosphatase CD45 gene and autoimmune hepatitis: evidence of a genetic link. Genes Immun 2003;4:79-81.
139. Seki S, Kitada T, Iwai S, Kadoya H, Yamada T, Kawada N et al. Immunohistochemical detection of Fas and apoptosis in type-1 autoimmune hepatitis. Hepatogastroenterology 2003;50:1274-7.
140. McKiernan S, Norris S, Vaughan R, Czaja AJ, Donaldson PT. MICA polymorphisms and susceptibility to autoimmune hepatitis: further evidence that susceptibility maps to the HLA class II region on chromosome 6p21.3. Hepatology 2002;36:503A.
141. Schramm C, Protschka M, Kohler HH, Podlech J, Reddehase MJ, Schirmacher P et al. Impairment of TGF-b signaling in T cells increases susceptibility to experimental autoimmune hepatitis in mice. Am J Physiol Gastrointest Liver Physiol 2003;284:G525-35.
142. Czaja AJ. Frequency and nature of the variant syndromes of autoimmune liver disease. Hepatology 1998;28:360-5.
143. Ben-Ari Z, Czaja AJ. Autoimmune hepatitis and its variant syndromes. Gut 2001;49:589-94.
144. Kenny RP, Czaja AJ, Ludwig J, Dickson ER. Frequency and significance of antimitochondrial antibodies in severe chronic active hepatitis. Dig Dis Sci 1986;31: 705-11.
145. Lohse AW, Meyer zum Buschenfelde KH, Kanzler FB, Gerken G, Dienes HP. Characterization of the overlap syndrome of primary biliary cirrhosis (PBC) and autoimmune hepatitis: evidence for it being a hepatitic form of PBC in genetically susceptible individuals. Hepatology 1999;29:1078-84.
146. Chazouilleres O, Wendum D, Serfaty L, Montebault S, Rosmorduc O, Poupon R. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy. Hepatology 1998; 28:296-301.
147. Czaja AJ. The autoimmune hepatitis/hepatitis C overlap syndrome: does it exist? In: Leuschner U, Broome U, Stiehl A editors. Cholestatic Liver Diseases: Therapeutic Options and Perspectives. Falk Symposium No. 136. Dordrecht, Netherlands: Kluwer Academic Publishers; 2004. p. 132-46.
148. Magrin S, Craxi A, Fabiano C, Simonetti RG, Fiorentino G, Marino L et al. Hepatitis C viremia in chronic liver disease: relationship to interferon-alpha or corticosteroid therapy. Hepatology 1994;19:273-9.
149. Vento S, DiPerri G, Garofano T, Cosco L, Concia E, Ferraro T et al. Hazards of interferon therapy for HBV-seronegative chronic hepatitis. Lancet 1989;2:926.
150. Shindo M, Di Bisceglie AM, Hoofnagle JH. Acute exacerbation of liver disease during interferon alfa therapy for chronic hepatitis C. Gastroenterology 1992;102: 1406-8.
151. Papo T, Marcellin P, Bernuau J, Durand F, Poynard T, Benhamou J-P. Autoimmune chronic hepatitis exacerbated by alpha-interferon. Ann Intern Med 1992;116: 51-3.
152. Garcia-Bury L, Garcia-Monzon C, Rodriguez S, Borque MJ, Garcia-Sanchez A, Iglesias R et al. Latent autoimmune hepatitis triggered during interferon therapy in patients with chronic hepatitis C. Gastroenterology 1995;108:1770-7.
153. Czaja AJ, Carpenter HA, Santrach PJ, Moore SB. Significance of human leukocyte antigens DR3 and DR4 in chronic viral hepatitis. Dig Dis Sci 1995;40:2098-106.
154. Czaja AJ, Magrin S, Fabiano C, Fiorentino G, Diquattro O, Craxi A et al. Hepatitis C virus infection as a determinant of behavior in type 1 autoimmune hepatitis. Dig Dis Sci 1995;40:33-40.
155. Tran A, Benzaken S, Yang G, Schneider S, Doglio A, Rampal A et al. Chronic hepatitis C and autoimmunity: good response to immunosuppressive therapy. Dig Dis Sci 1997;42:778-80.
156. Schiano TD, Te HS, Thomas RM, Hussain H, Bond K, Black M. Results of steroid-based therapy for the hepatitis C-autoimmune overlap syndrome. Am J Gastroenterol 2001;96:2984-91.
157. Saracco G, Touscoz A, Durazzo M, Rosina F, Donegani E, Chiandussi L et al. Antibodies and response to alpha-interferon in patients with chronic viral hepatitis. J Hepatol 1990;11:339-43.
158. Clifford BD, Donahue D, Smith L, Cable E, Luttig B, Manns M et al. High prevalence of serological markers of autoimmunity in patients with chronic hepatitis C. Hepatology 1995;21:613-9.
159. Fattovich G, Giustina G, Favarato S, Ruol A. A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon. J Hepatol 1996;24:38-47.
160. Czaja AJ, Ammon HV, Summerskill WHJ. Clinical features and prognosis of severe chronic active liver disease (CALD) after corticosteroid-induced remission. Gastroenterology 1980;78:518-23.
161. Hegarty JE, Nouri-Aria KT, Portmann B, Eddleston ALWF, Williams R. Relapse following treatment withdrawal in patients with autoimmune chronic active hepatitis. Hepatology 1983;3:685-9.
162. Czaja AJ, Menon KVN, Carpenter HA. Sustained remission after corticosteroid therapy for type 1 autoimmune hepatitis: a retrospective analysis. Hepatology 2002;35:890-7.
163. Czaja AJ. Emerging treatments for autoimmune hepatitis. Curr Drug Targets Inflamm Allergy 2002;1:317-26.
164. Czaja AJ. Treatment of autoimmune hepatitis. Semin Liver Dis 2002;22:365-77.
165. Lapierre P, Djilali-Saiah I, Vitozzi S, Alvarez F. A murine model of type 2 autoimmune hepatitis: xenoimmunization with human antigens. Hepatology 2004;39: 1066-74.
166. Vierling JM, Flores PA. Evolving new therapies of autoimmune hepatitis. Clin Liver Dis 2002;6:825-50.
167. Alvarez F, Ciocca M, Canero-Velasco C, Ramonet M, de Davila MT, Cuarterolo M et al. Short-term cyclosporine induces a remission of autoimmune hepatitis in children. J Hepatol 1999;30:222-7.
168. Malekzadeh R, Nasser-Moghaddam S, Kaviani M-J, Taheri H, Kamalian N, Sotoudeh M. Cyclosporin-A is a promising alternative to corticosteroids in autoimmune hepatitis. Dig Dis Sci 2001;46:1321-7.
169. Aqel BA, Machicao V, Rosser B, Satyanarayana R, Harnois DM, Dickson RC. Efficacy of tacrolimus in the treatment of steroid refractory autoimmune hepatitis. J Clin Gastroenterol 2004;38:805-9.
170. Richardson PD, James PD, Ryder SD. Mycophenolate mofetil for maintenance of remission in autoimmune hepatitis patients resistant to or intolerant of azathioprine. J Hepatol 2000;33:371-5.
171. Devlin SM, Swain MG, Urbanski SJ, Burak KW. Mycophenolate mofetil for the treatment of autoimmune hepatitis in patients refractory to standard therapy. Can J Gastroenterol 2004;18:321-6.
172. Czaja AJ, Carpenter HA. Empiric therapy of autoimmune hepatitis with mycophenolate mofetil: comparison with conventional treatment for refractory disease. J Clin Gastroenterol 2005;39:819-25.
173. Danielsson A, Prytz H. Oral budesonide for treatment of autoimmune chronic active hepatitis. Aliment Pharmacol Ther 1994;8:585-90.
174. Czaja AJ, Lindor KD. Failure of budesonide in a pilot study of treatment-dependent autoimmune hepatitis. Gastroenterology 2000;119:1312-6.
175. Jackson LD, Song E. Cyclosporin in the treatment of corticosteroid resistant autoimmune chronic active hepatitis. Gut 1995;36:459-61.
176. Fernandes NF, Redeker AG, Vierling JM, Villamil FG, Fong TL. Cyclosporine therapy in patients with steroid resistant autoimmune hepatitis. Am J Gastroenterol 1999;94:241-8.
177. Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 2000;47: 85-118.
178. Fridkis-Hareli M, Rosloniec EF, Fugger L, Strominger JL. Synthetic peptides that inhibit binding of the collagen type II 261-273 epitope to rheumatoid arthritis-associated HLA-DR1 and -DR4 molecules and collagen-specific T-cell responses. Hum Immunol 2000;61:640-50.
179. Guinan EC, Boussiotis VA, Neuberg D, Brennan LL, Hirano N, Nadler LM et al. Transplantation of anergic histoincompatible bone marrow allografts. N Engl J Med 1999;340:1704-14.
180. Wardrop RM, Whitacre CC. Oral tolerance in the treatment of inflammatory autoimmune diseases. Inflamm Res 1999;48:106-19.
181. Lohse AW, Dienes HP, Meyer zum Buschenfelde K-H. Suppression of murine experimental autoimmune hepatitis by T-cell vaccination or immunosuppression. Hepatology 1998;27:1536-43.
182. Rutgeerts P, D'Haens G, Targan S, Vasiliauskas E, Hanauer SB, Present DH et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 1999;117:761-9.
183. Nelson DR, Lauwers GY, Lau JY, Davis GL. Interleukin 10 treatment reduces fibrosis in patients with chronic hepatitis C: a pilot study of interferon nonresponders. Gastroenterology 2000;118:655-60.
184. Hannon GJ, Rossi JJ. Unlocking the potential of the human genome with RNA interference. Nature 2004; 431:371-8.
185. Song E, Lee S-K, Wang J, Ince N, Ouyang N, Min J et al. RNA interference targeting Fas protects mice from fulminant hepatitis. Nat Med 2003;9:347-51.
186. Touhy VK, Mathisen PM. Gene therapy for autoimmune diseases. In: Manns MP, Paumgartner G, Leuschner U editors. Immunology and Liver, Falk Symposium 114. Dordrecht: Kluwer Academic Publishers; 2000.p.376-85.
187. Schwartz RS. The new immunology - the end of immunosuppressive drug therapy? N Engl J Med 1999;340:1754-6.
188. Nagler A, Pines M, Abadi U, Pappo O, Zeira M, Rabbani E et al. Oral tolerization ameliorates liver disorders associated with chronic graft versus host disease in mice. Hepatology 2000;31:641-8.
189. Czaja AJ, Manns MP, McFarlane IG, Hoofnagle JH. Autoimmune hepatitis: the investigational and clinical challenges. Hepatology 2000;31:1194-200.
190. Vierling J. Autoimmune liver disease. Action Plan for Liver Disease Research. National Institute of Diabetes and Digestive and Liver Diseases, 2004. Available at: http://www.niddk.nih.gov/fund/divisions/ddn/ldrb/to pics.htm.